Over the Counter Cough and Cold Medication for Pediatric Use; Notice of Public Hearing; Correction, 51309 [E8-20370]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 170 / Tuesday, September 2, 2008 / Notices
management system. Electronic
comments or submissions will be
accepted by FDA only through FDMS at
https://www.regulations.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
IV. References
[Docket No. FDA–2008–N–0466]
The following references have been
placed on display in the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday. (FDA has verified the
Web site addresses, but FDA is not
responsible for any subsequent changes
to the Web sites after this document
publishes in the Federal Register.)
Over the Counter Cough and Cold
Medication for Pediatric Use; Notice of
Public Hearing; Correction
1. Sivapalasingam, S., et al. ‘‘Fresh
Produce: A Growing Cause of Outbreaks of
Foodborne Illness in the United States, 1973
through 1997,’’ Journal of Food Protection
67(10): 2342–53, 2004.
2. U.S. Food and Drug Administration,
1996 to 2007 Produce Outbreaks
(unpublished compilation).
3. U.S. Food and Drug Administration,
‘‘Guide to Minimize Microbial Food Safety
Hazards for Fresh Fruits and Vegetables,’’
October 26, 1998, available at https://
www.cfsan.fda.gov/~dms/prodguid.html.
4. U.S. Food and Drug Administration,
‘‘Produce Safety From Production to
Consumption: 2004 Action Plan to Minimize
Foodborne Illness Associated with Fresh
Produce Consumption,’’ October 2004,
available at https://www.cfsan.fda.gov/~dms/
prodpla2.html.
5. U.S. Food and Drug Administration,
‘‘Leafy Greens Safety Initiative—2nd year,’’
October 4, 2007, available at https://
www.cfsan.fda.gov/~dms/lettsaf2.html.
6. U.S. Food and Drug Administration,
‘‘Tomato Safety Initiative,’’ June 12, 2007,
available at https://www.cfsan.fda.gov/~dms/
tomsafe.html.
7. ‘‘Safety of Fresh Produce; Public
Hearings; Request for Comments’’ (72 FR
8750, February 27, 2007), Public hearings
held on March 20, 2007, and April 13, 2007,
https://www.regulations.gov/fdmspublic/
component/
main?main=DocketDetail&d=FDA–2007–N–
0380.
8. California Leafy Green Products Handler
Marketing Agreement, available at https://
www.caleafygreens.ca.gov.
II. Electronic Access
erowe on PROD1PC64 with NOTICES
Persons with access to the Internet
may obtain the document at https://
www.cfsan.fda.gov/~dms/
prodguid.html.
Dated: August 19, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–20187 Filed 8–29–08; 8:45 am]
BILLING CODE 4160–01–S
VerDate Aug<31>2005
14:40 Aug 29, 2008
Jkt 214001
Food and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
Notice of public hearing; request
for comments; correction.
ACTION:
SUMMARY: The Food and Drug
Administration is correcting a notice
that published in the Federal Register
on August 25, 2008 (73 FR 50033). The
notice announced a public hearing to
obtain input regarding over-the-counter
(OTC) cough and cold drugs marketed
for pediatric use. Due to some confusion
regarding electronic registration, this
notice revises the electronic registration
procedures, and corrects the address for
the contact person.
DATES: The correction is effective
September 2, 2008.
FOR FURTHER INFORMATION CONTACT:
Faith Dugan, Food and Drug
Administration, 10903 New Hampshire
Ave., rm. 6182, Silver Spring, MD
20993, 301–796–3446,
Faith.Dugan@fda.hhs.gov.
In FR Doc.
E8–19657, published on August 25,
2008 (73 FR 50033), the following
correction is made to ADDRESSES:
1. On page 50033, in the first and
second columns, the ADDRESSES section
is corrected to read as follows:
ADDRESSES: Submit written comments to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852.
E-mail electronic registration to:
Faith.Dugan@fda.hhs.gov. Anyone who
has already registered via https://
www.regulations.gov does not have to
re-register. The agency will accept those
registrations.
Submit electronic comments to https://
www.regulations.gov. All comments
should be identified with the docket
number found in brackets in the
heading of this document.
Transcripts of the hearing will be
available for review at the Division of
Dockets Management and on the
Internet at https://www.regulations.gov
approximately 30 days after the hearing.
For Registration to Attend and/or
Participate in the Hearing: Seating at the
hearing is limited. People interested in
attending should submit electronic
registration to Faith Dugan by close of
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
51309
business on September 15, 2008.
Registration is free and will be on a firstcome, first-served basis. Written or
electronic comments will be accepted
until December 2, 2008.
If you wish to make an oral
presentation at the hearing, you must
state your intention on your registration
submission (see ADDRESSES). To speak,
submit your name, title, business
affiliation, address, telephone and fax
numbers, and e-mail address. FDA has
included questions for comment in
section II of this document. You should
also identify by number each question
you wish to address in your
presentation. FDA will do its best to
accommodate requests to speak.
Individuals and organizations with
common interests are urged to
consolidate or coordinate their
presentations, and to request time for a
joint presentation. FDA will determine
the amount of time allotted to each
presenter and the approximate time that
each oral presentation is scheduled to
begin.
If you need special accommodations
because of a disability, please inform
Faith Dugan, (see For Information on the
Hearing Contact).
For Information on the Hearing
Contact: Faith Dugan, Food and Drug
Administration, 10903 New Hampshire
Ave., rm. 6182, Silver Spring, MD 20993
, 301–796–3446, FAX: 301–847–4752, email: Faith.Dugan@fda.hhs.gov.
Dated: August 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–20370 Filed 8–28–08; 11:15 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
E:\FR\FM\02SEN1.SGM
02SEN1
]]>Agencies
[Federal Register Volume 73, Number 170 (Tuesday, September 2, 2008)]
[Notices]
[Page 51309]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-20370]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0466]
Over the Counter Cough and Cold Medication for Pediatric Use;
Notice of Public Hearing; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public hearing; request for comments; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a notice that
published in the Federal Register on August 25, 2008 (73 FR 50033). The
notice announced a public hearing to obtain input regarding over-the-
counter (OTC) cough and cold drugs marketed for pediatric use. Due to
some confusion regarding electronic registration, this notice revises
the electronic registration procedures, and corrects the address for
the contact person.
DATES: The correction is effective September 2, 2008.
FOR FURTHER INFORMATION CONTACT: Faith Dugan, Food and Drug
Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD
20993, 301-796-3446, Faith.Dugan@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In FR Doc. E8-19657, published on August 25,
2008 (73 FR 50033), the following correction is made to ADDRESSES:
1. On page 50033, in the first and second columns, the ADDRESSES
section is corrected to read as follows:
ADDRESSES: Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852.
E-mail electronic registration to: Faith.Dugan@fda.hhs.gov. Anyone
who has already registered via https://www.regulations.gov does not have
to re-register. The agency will accept those registrations.
Submit electronic comments to https://www.regulations.gov. All
comments should be identified with the docket number found in brackets
in the heading of this document.
Transcripts of the hearing will be available for review at the
Division of Dockets Management and on the Internet at https://
www.regulations.gov approximately 30 days after the hearing.
For Registration to Attend and/or Participate in the Hearing:
Seating at the hearing is limited. People interested in attending
should submit electronic registration to Faith Dugan by close of
business on September 15, 2008. Registration is free and will be on a
first-come, first-served basis. Written or electronic comments will be
accepted until December 2, 2008.
If you wish to make an oral presentation at the hearing, you must
state your intention on your registration submission (see ADDRESSES).
To speak, submit your name, title, business affiliation, address,
telephone and fax numbers, and e-mail address. FDA has included
questions for comment in section II of this document. You should also
identify by number each question you wish to address in your
presentation. FDA will do its best to accommodate requests to speak.
Individuals and organizations with common interests are urged to
consolidate or coordinate their presentations, and to request time for
a joint presentation. FDA will determine the amount of time allotted to
each presenter and the approximate time that each oral presentation is
scheduled to begin.
If you need special accommodations because of a disability, please
inform Faith Dugan, (see For Information on the Hearing Contact).
For Information on the Hearing Contact: Faith Dugan, Food and Drug
Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD
20993 , 301-796-3446, FAX: 301-847-4752, e-mail:
Faith.Dugan@fda.hhs.gov.
Dated: August 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-20370 Filed 8-28-08; 11:15 am]
BILLING CODE 4160-01-S
